A therapeutic, two-antibody COVID-19 treatment “cocktail” from Regeneron and the Biomedical Advanced Research and Development Authority moved to its first clinical trial, the developers earlier this month announced.

The REGN-COV2 treatment contains two neutralizing monoclonal antibodies. It is believed to have the potential to be one of the first therapeutics specifically designed to inhibit SARS-COV-2.

Related News Articles

Headline
A new AHA podcast explores how rural hospitals have found new ways to deliver care to patients with COVID-19. Brian Evans, CEO of Clarke County Hospital in…
Headline
Certain groups of workers showed significantly more absenteeism in March and April 2020, suggesting a link to COVID-19 exposure, according to a new study…
Headline
The Department of Health and Human Services today announced that it will distribute over $4 billion in additional funds from the Public Health and Social…
Perspective
Wear a mask. Wash your hands. Keep your distance. These are three simple actions we know that will stop the spread of COVID-19. The AHA, American Medical…
Headline
The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune…
Headline
Gilead Sciences yesterday said it is starting phase one clinical study of inhaled remdesivir for potential outpatient treatment of COVID-19. In a statement,…